99 related articles for article (PubMed ID: 23759730)
41. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
42. The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma.
Martínez-Romero C; Rooman I; Skoudy A; Guerra C; Molero X; González A; Iglesias M; Lobato T; Bosch A; Barbacid M; Real FX; Hernández-Muñoz I
J Pathol; 2009 Oct; 219(2):205-13. PubMed ID: 19585519
[TBL] [Abstract][Full Text] [Related]
43. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
44. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
[TBL] [Abstract][Full Text] [Related]
45. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
Mol Cancer Res; 2017 Feb; 15(2):201-212. PubMed ID: 28108627
[TBL] [Abstract][Full Text] [Related]
46. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
47. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
Hartley CP; Mahajan AM; Selvaggi SM; Rehrauer WM
Cancer Cytopathol; 2017 Nov; 125(11):838-847. PubMed ID: 29024530
[TBL] [Abstract][Full Text] [Related]
48. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
49. Pancreatic cancer: A matter of timing.
Seton-Rogers S
Nat Rev Cancer; 2015 May; 15(5):256-7. PubMed ID: 25855403
[No Abstract] [Full Text] [Related]
50. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
52. K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.
Li T; Zheng Y; Sun H; Zhuang R; Liu J; Liu T; Cai W
Med Oncol; 2016 Jul; 33(7):61. PubMed ID: 27225938
[TBL] [Abstract][Full Text] [Related]
53. K-Ras mutations and benign pancreatic disease.
Löhr M; Maisonneuve P; Lowenfels AB
Int J Pancreatol; 2000 Apr; 27(2):93-103. PubMed ID: 10862508
[TBL] [Abstract][Full Text] [Related]
54. E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice.
Stark AP; Chang HH; Jung X; Moro A; Hertzer K; Xu M; Schmidt A; Hines OJ; Eibl G
Surgery; 2015 Dec; 158(6):1564-72. PubMed ID: 26297056
[TBL] [Abstract][Full Text] [Related]
55. Mouse Models of Pancreatic Ductal Adenocarcinoma.
Ponz-Sarvise M; Tuveson DA; Yu KH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):609-17. PubMed ID: 26226900
[TBL] [Abstract][Full Text] [Related]
56. Insights into the role of nicotine in pancreatic stem cell activation and acinar dedifferentiation.
Ponnusamy MP; Batra SK
Gastroenterology; 2014 Nov; 147(5):962-5. PubMed ID: 25265575
[No Abstract] [Full Text] [Related]
57. Endogenous Hyperinsulinemia Contributes to Pancreatic Cancer Development.
Zhang AMY; Magrill J; de Winter TJJ; Hu X; Skovsø S; Schaeffer DF; Kopp JL; Johnson JD
Cell Metab; 2019 Sep; 30(3):403-404. PubMed ID: 31378465
[No Abstract] [Full Text] [Related]
58. Nuclear receptor subfamily 5 group A member 2 (NR5A2): role in health and diseases.
Sandhu N; Rana S; Meena K
Mol Biol Rep; 2021 Dec; 48(12):8155-8170. PubMed ID: 34643922
[TBL] [Abstract][Full Text] [Related]
59. Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer.
Cancer Discov; 2022 Apr; 12(4):878-879. PubMed ID: 35373275
[TBL] [Abstract][Full Text] [Related]
60. Maternal inheritance pattern of hereditary pancreatitis in patients with pancreatic carcinoma.
Lerch MM; Ellis I; Whitcomb DC; Keim V; Simon P; Howes N; Rutherford S; Domschke W; Imrie C; Neoptolemos JP
J Natl Cancer Inst; 1999 Apr; 91(8):723-4. PubMed ID: 10218513
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
